The phase III EVOKE 01 study (N = 603) tested sacituzumab govitecan versus docetaxel in metastatic non-small cell lung cancer after progression on platinum-based CT, anti-PD-L1, or AGA-targeted treatments. Here, CD274 is linked to non-small cell lung carcinoma.